A team of researchers from Sweden, France, Belgium and Switzerland has found a way to reverse resistance to an antibiotic drug used to treat tuberculosis. In their paper published in the journal Science, the team describes how they screened compounds that activated different pathways to activate ethionaide, a compound used to treat tuberculosis.
The researchers are currently working with GlaxoSmithKline and Biotech Bioversys to further develop the small prototype molecule into a drug that can be mass produced and sold.
(Medical Xpress)—A team of researchers from Sweden, France, Belgium and Switzerland has found a way to reverse resistance to an antibiotic drug used to treat tuberculosis. In their paper published in the journal Science, the team describes how they screened compounds that activated different pathways to activate ethionaide, a compound used to treat tuberculosis.
The development of antibiotics to treat bacterial infections has very clearly made the world a healthier place. Unfortunately, over time, bacteria have been evolving to thwart such compounds, putting us all at risk once again. Because of that, scientists have been searching for new treatments, or in some cases, ways to make old treatments work again using new techniques. In this new effort, the researchers have found a way to make ethionaide, a prodrug (a compound that is metabolized in the body to produce a desired drug), become effective again in patients infected with resistant strains of Mycobacterium tuberculosis.
